Datopotamab deruxtecan for previously treated advanced non-small-cell lung cancer

Datopotamab deruxtecan is being developed to treat advanced stage non-small-cell lung cancer (NSCLC). NSCLC is diagnosed at an advanced stage in nearly 50% of patients and often has a poor prognosis with worsening outcomes after each line of subsequent therapy. While initial treatment consisting of immunotherapy with or without chemotherapy has improved outcomes for patients with NSCLC without actionable genomic alterations, disease progression still occurs in the majority of patients and additional treatment strategies in this setting are needed. Currently in phase III clinical trials.